A novel formulation of selegiline for the treatment of Parkinson's disease.
The Parkinson's Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA.
James W
JW
Tetrud
William C
WC
Koller
D000042:Absorption; D000284:Administration, Oral; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001711:Biotransformation; D005544:Forecasting; D005612:Freeze Drying; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D009061:Mouth Mucosa / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012642:Selegiline / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D012995:Solubility; D013607:Tablets; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D013607:Tablets; D012642:Selegiline